Cardinal Health enters the week after earnings with the Street uniformly bullish, a fresh $5 billion buyback authorization in hand — and nearly every C-suite executive heading for the exit at the same time.
The insider story is the sharpest tension in this note. On August 14, CEO Jason Hollar sold 103,449 shares at $235.17, pocketing roughly $24.3 million in a single transaction. He wasn't alone. The CFO, Chief Legal Officer, Chief Information Officer, two divisional CEOs, and two other executives all sold on the same day, totalling well over $50 million in combined proceeds. The 90-day net value of insider transactions is a positive $53.7 million — but that figure reflects option awards and earlier activity rather than a genuine accumulation signal. Every recent open-market transaction has been a sale. That cluster of simultaneous C-suite selling, one week after reporting a strong fiscal year-end print, is the kind of pattern that is hard to ignore even when the fundamental story reads as clean.
The borrow market offers no corroboration for bearish conviction. Short interest has drifted down about 3.3% on the week to 2.76% of free float — a low and declining position that doesn't suggest an organised bear thesis. Cost to borrow has risen roughly 19% over the past seven days to 0.35%, a move that sounds dramatic in percentage terms but leaves it firmly in near-zero territory in absolute terms. Availability is extraordinarily loose at over 9,000% — far more shares are available to borrow than are currently lent out, meaning any short seller who wants in faces no friction whatsoever. Options positioning is slightly more cautious than usual: the put/call ratio runs at 0.80, about 1.3 standard deviations above its 20-day mean of 0.75. That's a modest tilt toward hedging, not a fear trade. Taken together, the lending market is describing a stock where bears have little conviction and shorts have largely been covering since late July.
The Street read the earnings print as unambiguously positive. RBC Capital initiated coverage this week with an Outperform and a $276 target — fresh enough to register as a new institutional voice entering the story. TD Cowen raised its target to $280 and JP Morgan lifted to $260 from $215, a notable move given JP Morgan had been the visible holdout at Neutral for months. Barclays, Citigroup, Evercore ISI, Morgan Stanley, UBS, and Wells Fargo all raised targets in the two days around the August 11 print; none cut a rating. The consensus mean now sits at $270.94, roughly 15% above the current price of $234.98. EPS momentum remains a standout factor — 79th percentile on 30-day momentum and 90th percentile on the 90-day reading — and forward EPS growth ranks in the 82nd percentile year-on-year. The bull case centres on Cardinal's growing radiopharmaceuticals footprint and specialty distribution expansion; the bear case flags reliance on GLP-1 volume, competitive pressure in generic drug pricing, and Inflation Reduction Act exposure. Despite the near-uniform analyst enthusiasm, the stock has slipped 2.2% this week, underperforming close peer MCK, which fell 3.6%, while COR dropped 5.3% — so Cardinal is actually holding up relatively better within the distribution cohort.
Wellington Management stands out in the institutional register, having added 10.6 million shares in Q2 — by far the largest institutional move in the snapshot — taking its position to 14.9 million shares, or 6.4% of the company. BlackRock and State Street also added modestly in July. The ownership picture is therefore one of large passive and active managers adding while corporate insiders reduce — a divergence in direction that characterises a stock priced for execution rather than discovery.
The next earnings event is scheduled for October 30. Between now and then, the question worth tracking is whether the stock can sustain the $235 level against continued insider supply — and whether the RBC initiation and JP Morgan target lift translate into incremental institutional buying that absorbs what the C-suite is distributing.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
